Pharmacological targeting of the ephrin receptor kinase signalling by GLPG1790 in vitro and in vivo reverts oncophenotype, induces myogenic differentiation and radiosensitizes embryonal rhabdomyosarcoma cells

Pharmacological targeting of the ephrin receptor kinase signalling by GLPG1790 in vitro and in vivo reverts oncophenotype, induces myogenic differentiation and radiosensitizes embryonal rhabdomyosarcoma cells

Abstract Background EPH (erythropoietin-producing hepatocellular) receptors are clinically relevant targets in several malignancies. This report describes the effects of GLPG1790, a new potent pan-EPH inhibitor, in human embryonal rhabdomyosarcoma (ERMS) cell lines. Methods EPH-A2 and Ephrin-A1 mRNA...

Full description

Bibliographic Details
Main Authors: Francesca Megiorni, Giovanni Luca Gravina, Simona Camero, Simona Ceccarelli, Andrea Del Fattore, Vincenzo Desiderio, Federica Papaccio, Heather P. McDowell, Rajeev Shukla, Antonio Pizzuti, Filip Beirinckx, Philippe Pujuguet, Laurent Saniere, Ellen Van der Aar, Roberto Maggio, Francesca De Felice, Cinzia Marchese, Carlo Dominici, Vincenzo Tombolini, Claudio Festuccia, Francesco Marampon
Format: Article
Language:English
Published: BMC 2017-10-01
Series:Journal of Hematology & Oncology
Subjects:
Rhabdomyosarcoma
GLPG1790
Ephrin
Cancer stem cell
Radiation therapy
Tumour xenografts
Online Access:http://link.springer.com/article/10.1186/s13045-017-0530-z

Internet

http://link.springer.com/article/10.1186/s13045-017-0530-z

Similar Items